Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

ZJYL vs ZKH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZJYL Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

ZJYL Overall Winner 6-Pillar Tally: ZJYL 4 – 1 ZKH (1 Tie) Matrix Metrics: ZJYL 6 – 4 ZKH

As of Nov 19, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over ZKH Group Limited (ZKH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ZJYL carries a Unified Composite Score of 40.6/100 (SELL) at $3.34 (N/M Forward P/E, 2.1% operating margin), whereas ZKH carries 48.9/100 (HOLD) at $1.47 (3.3x Forward P/E, -0.8% operating margin).

  • Composite vs. Pillar Nuance: While ZKH currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ZJYL 40.6/100 SELL), ZJYL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -0.8% operating margin) and revenue trajectory (-9.7% vs. +12.8% YoY).
  • Technical & Structure Timing Caution: ZJYL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.0); meanwhile ZKH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZJYL vs ZKH
ZJYL NASDAQ Head-to-Head Winner
JIN MEDICAL INTERNATIONAL LTD. Ordinary Shares
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$3.34
-0.6% 1D
Market Cap $534.9M
TTM Revenue $508M
Forward P/E N/M
Beta / 30D Vol 13.88β · 178% Vol
Unified Composite Score
40.6 / 100 SELL
Tech 24.0 Fund 31.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.1% over 20 days), RSI 55
RSI-14: 55.0 · SMA20: $3.04 · SMA50: $2.43
ZKH NYSE
ZKH Group Limited American Depositary Shares, each representing thirty-five (35) Class A Ordinary Shares
Retail-Building Materials, Hardware, Garden Supply
$1.47
+4.26% 1D
Market Cap $222.5M
TTM Revenue $9.44B
Forward P/E 3.3x
Beta / 30D Vol -0.20β · 94% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 65.0 Fund 62.0 Flow 50.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $1.47 · SMA50: $2.06

6-Pillar Scorecard Institutional Category Breakdown (ZJYL 4 – 1 ZKH)

Columns: Metric · ZJYL · ZKH
1. Valuation Multiples ZJYL
Forward P/E N/M 3.3x
Trailing P/E 17.7x 28.2x
PEG Ratio N/M N/M
EV / Revenue 1.1x N/M
2. Growth & Scale ZKH
Revenue Growth (YoY) -9.7% +12.8%
Earnings Growth (YoY) -32.0% +0.0%
TTM Revenue (USD) $508M $9.44B
Market Cap $534.9M $222.5M
3. Profitability & Quality ZJYL
Gross Margin 31.3% 16.6%
Operating Margin 2.1% -0.8%
Net Profit Margin 5.9% -0.0%
Return on Equity (ROE) 4.0% -0.1%
4. Balance Sheet & Cash Flow ZJYL
Cash Generation (TTM) $17M EBITDA -$34M EBITDA
Cash Flow Margin 3.3% EBITDA Mgn -0.4% EBITDA Mgn
Net Cash / Leverage $3.87 Book/Sh · 4.0% ROE $2.70 Book/Sh · -0.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ZJYL
OpEx & R&D Intensity 29.2% of Rev ($148M) 17.4% of Rev ($1.64B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Internet Retail Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZJYL (6) vs ZKH (4)
Institutional Metric ZJYL ZKH Criterion Row Edge
Market Capitalization
Scale
$534.9M $222.5M Larger Scale ZJYL
Trailing P/E Ratio
Valuation
17.7x 28.2x Lower Multiple ZJYL
Forward P/E Ratio
Valuation
N/M 3.3x Lower Multiple ZKH
Revenue Growth (YoY)
Growth
-9.7% +12.8% Higher Growth ZKH
Operating Margin (TTM)
Profitability
2.1% -0.8% Higher Margin ZJYL
Net Profit Margin
Profitability
5.9% -0.0% Higher Margin ZJYL
Return on Equity (ROE)
Capital Efficiency
4.0% -0.1% Higher ROE ZJYL
52-Week Range Position
Momentum
67% ($0–$5) 10% ($1–$4) Stronger Trend ZJYL
Beta / 30D Volatility
Risk Regime
13.88β · 178% Vol -0.20β · 94% Vol Lower Realized Risk ZKH
Unified Institutional Score
Composite Signal
40.6 / 100 (SELL) 48.9 / 100 (HOLD) Higher Composite ZKH
Trailing 12M Revenue (USD)
Operating Scale
$508M $9.44B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
31.3% 16.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17M EBITDA ($3.87 Book/Sh · 4.0% ROE) -$34M EBITDA ($2.70 Book/Sh · -0.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZJYL +76.68 pp
ZJYL: +59.73% · ZKH: -16.95%
3M Horizon ZJYL +59.18 pp
ZJYL: +9.87% · ZKH: -49.31%
6M Horizon ZJYL +95.68 pp
ZJYL: +45.85% · ZKH: -49.83%
1Y Horizon ZJYL +1188.84 pp
ZJYL: +1137.04% · ZKH: -51.8%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZJYL vs ZKH. Trailing 12-month operating profitability (ZJYL 2.1% vs ZKH -0.8%) and valuation multiples (ZJYL N/M vs ZKH 3.3x Forward P/E) are benchmarked directly in Pillar 4 below.

ZJYL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$508M
Gross Margin31.3%
Op. Margin2.1%
ROE / Fwd P/E4.0% · N/M
ZKH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$9.44B
Gross Margin16.6%
Op. Margin-0.8%
ROE / Fwd P/E-0.1% · 3.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZJYL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZJYL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZKH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZKH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZJYL Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $534.9M market capitalization and 2.1% operating margin.
OpEx & R&D Reinvestment 29.2% of Rev ($148M)
90D Engineering Disclosures 0 Published
ZKH Moat Profile Cyclical / Execution-Driven Positioning
Internet Retail Operator
Competes within the Internet Retail value chain with $222.5M market capitalization and -0.8% operating margin.
OpEx & R&D Reinvestment 17.4% of Rev ($1.64B)
90D Engineering Disclosures 0 Published

Investor FAQ ZJYL vs ZKH Key Questions & Quantitative Answers

As of Nov 19, 2026, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) is the stronger overall head-to-head candidate over ZKH Group Limited (ZKH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ZJYL carries a Unified Composite Score of 40.6/100 (SELL) at $3.34 (N/M Forward P/E, 2.1% operating margin), whereas ZKH carries 48.9/100 (HOLD) at $1.47 (3.3x Forward P/E, -0.8% operating margin). Composite vs. Pillar Nuance: While ZKH currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. ZJYL 40.6/100 SELL), ZJYL captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.1% vs. -0.8% operating margin) and revenue trajectory (-9.7% vs. +12.8% YoY). Technical & Structure Timing Caution: ZJYL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.0); meanwhile ZKH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ZKH leads the Growth & Scale pillar: ZJYL posts -9.7% YoY revenue growth and -32.0% YoY earnings growth on $508M TTM revenue (31.3% gross margin, 2.1% operating margin), compared with ZKH at +12.8% YoY revenue growth and +0.0% YoY earnings growth on $9.44B TTM revenue (16.6% gross margin, -0.8% operating margin). On trailing 12-month operating scale, ZJYL generates $508M in USD-normalized revenue versus $9.44B for ZKH. In operating R&D and SG&A reinvestment, ZJYL deploys 29.2% of Rev ($148M) (0 90-day corporate R&D disclosures) versus 17.4% of Rev ($1.64B) (0 disclosures) for ZKH.

ZJYL screens cheaper on headline valuation multiples. ZJYL trades at N/M Forward P/E, 17.7x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (3.3% EBITDA margin), whereas ZKH trades at 3.3x Forward P/E, 28.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (-0.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZJYL (4.0% ROE) versus ZKH (-0.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ZJYL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (13.88β · 178% Vol realized risk). By comparison, ZKH carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.20β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

ZKH Group Limited American Depositary Shares, each representing thirty-five (35) Class A Ordinary Shares (ZKH) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.